| payload |
{"created_at":"2026-04-11T03:10:51.104 {"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:7216d10fa5142a37","evidence_event_ids":["evt_a1b0efdbff3a"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150470.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150470.txt","company":"Tempest Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150470.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_3bfb9b9b8e7ff8a1","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150470.txt","content_type":"text/plain","enriched_at":"2026-04-11T06:08:11.608958+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"424B3","final_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150470.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150470.txt","source_event_id":"evt_a1b0efdbff3a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"424B3","fp":"dd979d1061831a4b","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-10","2026-04-11","2026-04-09","2026-04-08","2026-03-20"],"entities":[{"asset_class":"equity","name":"Tempest Therapeutics, Inc.","relevance":"high","symbol":"TPST","type":"issuer"},{"asset_class":"warrants","name":"Series A Warrants","relevance":"medium","symbol":"","type":"security"},{"asset_class":"warrants","name":"Series B Warrants","relevance":"medium","symbol":"","type":"security"},{"asset_class":"warrants","name":"Pre-Funded Warrants","relevance":"medium","symbol":"","type":"security"},{"asset_class":"market","name":"Nasdaq Capital Market","relevance":"low","symbol":"","type":"exchange"}],"event_type":"listing","information_gaps":["What specifically changed versus the prior known state is not provided in the signal text (no prior filing details included).","The prospectus excerpt does not include the full \u201cProspectus Summary,\u201d \u201cPlan of Distribution,\u201d or the complete list of selling stockholders.","No financial guidance or company financial implications beyond the statement that the company will not receive proceeds are disclosed in the provided text."],"key_facts":["Form 424B3 was filed pursuant to Rule 424(b)(3) for Registration No. 333-294843.","The prospectus covers resale/offer of up to an aggregate 2,777,781 shares of Tempest Therapeutics, Inc. common stock (par value $0.001 per share).","Share breakdown disclosed: 462,964 shares; 925,927 shares issuable upon exercise of outstanding Series A Warrants; 925,927 shares issuable upon exercise of outstanding Series B Warrants; and 462,963 shares issuable upon exercise of pre-funded warrants.","The shares were acquired by selling stockholders under a securities purchase agreement dated March 20, 2026.","The company states it will not receive any proceeds from the sale of the shares by selling stockholders.","Selling stockholders may sell shares from time to time through public or private transactions at prevailing market prices or related/negotiated prices.","Selling stockholders bear underwriting fees/commissions/discounts (if any) and transfer taxes; the company bears other registration costs/expenses/fees.","The company\u2019s common stock is listed on Nasdaq Capital Market under trading symbol \u201cTPST.\u201d","The prospectus date is April 9, 2026; it references a closing price of $1.56 per share on April 8, 2026."],"numeric_claims":[{"label":"Aggregate shares covered","value":"2,777,781"},{"label":"Series A warrant shares","value":"925,927"},{"label":"Series B warrant shares","value":"925,927"},{"label":"Pre-funded warrant shares","value":"462,963"},{"label":"Direct common shares","value":"462,964"},{"label":"Common stock par value","value":"$0.001 per share"},{"label":"Closing price on April 8, 2026","value":"$1.56 per share"}],"primary_claim":"The company filed Form 424B3 to register the offer and resale of up to an aggregate 2,777,781 shares of its common stock by selling stockholders, with no proceeds to the company.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Tempest Therapeutics, Inc. filed a Form 424B3 prospectus supplementing a Form S-3 shelf registration to register resale of up to 2,777,781 shares of common stock held by selling stockholders. The filing states the company will not receive proceeds from the sales and provides the share breakdown tied to warrants and pre-funded warrants.","topics":["SEC filing","prospectus","Form 424B3","Form S-3 shelf registration","common stock resale","warrants","Nasdaq listing"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 424B3 \u00b7 Tempest Therapeutics, Inc. \u00b7 Filed 20260410","ticker":"TPST","tickers":["TPST"],"title":"TPST filed 424B3","url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-150470.txt"}}... |